Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

mRNA-4203

Vaccine (mRNA vaccine) · Immune activation, directed at PRAME · developed by Immatics US

Phase 1 Most advanced trial
IMTX Developer
1 Registered trials

What is mRNA-4203?

mRNA-4203 (anzu-cel) is a lipid nanoparticle-encapsulated mRNA cancer vaccine encoding the tumor-associated antigen PRAME. After uptake and translation by antigen presenting cells, the PRAME epitope is presented on MHC molecules to induce cytotoxic and memory T-cell responses against PRAME-expressing cancer cells. It is studied in cutaneous melanoma and synovial sarcoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
anzu-cel
Drug type
Vaccine (mRNA vaccine)
Targets
PRAME (antigen)
Mechanism
Immune activation, directed at PRAME
Pathways
MHC presentation, cytotoxic T-lymphocyte response, memory T-cell response
Therapy area
Oncology
Developer
Immatics US, Inc. (IMTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06946225 Phase 1 Cutaneous Melanoma Recruiting IMTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cutaneous MelanomaSynovial Sarcoma

Other drugs acting on PRAME

More from Immatics US

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the IMTX page.

Follow IMTX, the company behind mRNA-4203

See IMTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.